Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Chelation therapy Stories

2013-12-03 23:30:33

The December issue of the Journal of Medical Toxicology focuses on the use of chelating drugs for treatment of poisoning due to metals such as mercury and lead. Many of the articles are adapted from presentations delivered at the conference ‘Use & Misuse of Metal Chelation Therapy’ held at the CDC in Atlanta in 2012 and supported by the CDC’s Agency for Toxic Substances and Disease Registry (ATSDR) Cooperative Agreement between ACMT and ATSDR. Phoenix, Arizona (PRWEB)...

2013-11-19 16:22:28

MIAMI BEACH, Fla., Nov. 19, 2013 /PRNewswire-USNewswire/ -- Chelation treatments reduce cardiovascular events, such as heart attacks, and death in patients with diabetes but not in those who did not have diabetes, according to analyses of data from the National Institutes of Health-funded Trial to Assess Chelation Therapy (TACT). However, researchers say more research is needed before it's known whether this promising finding leads to a treatment option. "These are striking results...

2013-07-09 23:28:37

Resonance Health is pleased to announce the peer reviewed publication of a significant validation study for FerriScan R2-MRI. (PRWEB) July 09, 2013 FerriScan R2-MRI has gained international acknowledgement as the gold standard for non-invasive MRI measurement of liver iron concentration. This is now further substantiated by the publication of the paper demonstrating that the technology can be used in different MRI centres on different makes and models of scanners with no impact on the...

2013-03-27 12:37:48

Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes, but the findings do not support the routine use of chelation therapy for treatment of patients who have had a heart attack, according to a study in the March...

2013-03-05 08:30:13

EULESS, Texas, March 5, 2013 /PRNewswire/ -- Dr. Brett Payne, director at Innovate Health, has announced that the clinic is now offering cardiovascular chelation therapy, IV vitamin infusions, metabolic weight loss and hormone options, and full body detoxification and cleansing. The array of new services is specially designed to eliminate harmful toxins and promote the body's cellular health. "Individuals are bombarded with toxins every day from the atmosphere and their environment," said...

Controversial Treatment For Autism Spectrum Disorder Proven Ineffective And Harmful
2012-11-30 11:44:17

Lawrence LeBlond for redOrbit.com - Your Universe Online A new study conducted by researchers at Baylor University found that a controversial autism treatment is ineffective and harmful. Called chelation, this treatment attempts to eliminate metals from the body in attempt to lessen the grasp of autism spectrum disorder (ASD). Study coauthor Tonya N. Davis, PhD, assistant professor of educational psychology in Baylor´s School of Education, said: “The chemical substances used...

2012-10-24 04:00:42

To meet the demands of those seeking hormone replacement therapy in Florida, Total Rejuvenation has opened its new medical center in Jupiter, FL. The exclusive center features new rejuvenating services along with industry-leading hormone therapy. Jupiter, FL (PRWEB) October 23, 2012 Expanding its services related to hormone replacement therapy in Florida, Total Rejuvenation opens the doors of its new medical center in Jupiter, FL. At the Total Age Management Center, patients can take...

2011-12-13 10:30:00

EAST HANOVER, N.J., Dec. 13, 2011 /PRNewswire/ -- Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade(®) (deferasirox) in patients with non-transfusion-dependent thalassemia (NTDT), show that Exjade can significantly reduce iron overload. These data were presented today at the 53rd Annual Meeting of the American Society of Hematology in San Diego. THALASSA investigated whether patients with...

2011-10-14 14:10:00

SILVER SPRING, Md., Oct. 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Patients with thalassemia have excess iron in the body from the frequent blood transfusions...

2011-09-14 12:23:00

TORONTO, Sept. 14, 2011 /PRNewswire/ -- ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox(®) (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate. "We are very pleased that ODAC members responded positively to the totality...